The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
The Effects of Different Formulations of Oral Contraceptive Agents on Lipid and Carbohydrate Metabolism
Abstract
BACKGROUND: Oral contraceptives can induce changes in lipid and carbohydrate metabolism similar to those associated with an increased risk of coronary heart disease, including increased serum triglyceride, low-density lipoprotein (LDL) cholesterol, and insulin levels and decreased high-density lipoprotein (HDL) cholesterol levels. In this study, we examined whether modification of the type or dose of progestin in oral-contraceptive preparations diminishes these changes. METHODS: We measured plasma lipoprotein levels and performed oral glucose-tolerance tests in a cross section of 1060 women who took one of nine types of oral contraceptives for at least three months and 418 women who took none. Seven of the contraceptive formulations contained various doses and types of progestin: levonorgestrel in low (150 micrograms), high (250 micrograms), and triphasic (50 to 125 micrograms) doses; norethindrone in low (500 micrograms), high (1000 micrograms), and triphasic (500 to 1000 micrograms) doses; and a new progestin, desogestrel, in one dose (150 micrograms). All seven contained 30 to 40 micrograms of ethinyl estradiol. Two additional formulations contained progestin alone. RESULTS: As compared with controls, women taking combination drugs did not have increased serum total cholesterol levels but did have increases of 13 to 75 percent in fasting triglyceride levels. Levels of LDL cholesterol were reduced by 14 percent in women taking the combination containing desogestrel and by 12 percent in those taking low-dose norethindrone. Levels of HDL cholesterol were lowered by 5 percent and 16 percent by the combinations containing low-dose and high-dose levonorgestrel, respectively; these decreases were due to reductions of 29 percent and 43 percent, respectively, in the levels of HDL subclass 2. The combination pill containing high-dose norethindrone did not affect HDL cholesterol levels, whereas that containing low-dose norethindrone increased HDL cholesterol levels by 10 percent. The desogestrel combination increased HDL cholesterol levels by 12 percent. Levels of apolipoproteins A-I, A-II, and B were generally increased by combination drugs. Depending on the dose and type of progestin, combination drugs were associated with plasma glucose levels on the glucose-tolerance test that were 43 to 61 percent higher than in controls, insulin responses 12 to 40 percent higher, and C-peptide responses 18 to 45 percent higher. Progestin-only formulations had only minor metabolic effects. CONCLUSIONS: The appropriate dose and type of progestin may reduce the adverse effects of oral contraceptives on many metabolic markers of risk for coronary heart disease. Progestin-only formulations or combinations containing desogestrel or low-dose norethindrone were associated wtih the most favorable profiles.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Estrogens have a positive effect on lipid metabolism, increasing HDL-C and decreasing LDL-C, while progestins, depending on their type and androgenicity, may counteract these positive estrogenic effects [23-25] .”
From Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone (2021) · cites this paper as [23]
In the citing paper
“Progestin-only oral contraceptives do not affect blood glucose values or BP in women with type 1 diabetes (231, 232)”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [232]
In the citing paper
“In the CARDIA study (Coronary Artery Risk Development in Young Adults), which did not distinguish between various formulations, oral contraceptive users had higher triglyceride levels than nonusers, despite their use being associated with lower fasting glucose levels and reduced odds of DM.”
From Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association (2011) · cites this paper as [319]
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Banting lecture 1988. Role of insulin resistance in human disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diabetes.37.12.1595 · Cited by 3,811
Quantitative Determination of Serum Triglycerides by the Use of Enzymes
Bucolo, G., & David, H. (1973) · Clinical Chemistry · doi:10.1093/clinchem/19.5.476 · Cited by 3,188
Serum Cholesterol, Lipoproteins, and the Risk of Coronary Heart Disease: The Framingham Study
KANNEL, W. B., CASTELLI, W. P., GORDON, T., & MCNAMARA, P. M. (1971) · Annals of Internal Medicine · doi:10.7326/0003-4819-74-1-1 · Cited by 2,057
Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen
Trinder, P. (1969) · Journal of Clinical Pathology · doi:10.1136/jcp.22.2.158 · Cited by 1,656
High-Density Lipoprotein — The Clinical Implications of Recent Studies
Desforges, J. F., Gordon, D. J., & Rifkind, B. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911093211907 · Cited by 1,547
Warnick, G. R., & Albers, J. J. (1978) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41577-9 · Cited by 1,250
Siedel, J., Hägele, E. O., Ziegenhorn, J., & Wahlefeld, A. W. (1983) · Clinical Chemistry · doi:10.1093/clinchem/29.6.1075 · Cited by 942
Gidez, L. I., Miller, G. J., Burstein, M., Slagle, S., & Eder, H. A. (1982) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38059-7 · Cited by 757
Research works printed but not linked: 3
- 1966, Lancet, 2, 799
- Sturtevant, 1989, Int J Fertil, 34, 323
- Nikkilä EA, Tikkanen MJ, Kuusi T. Effects of progestins on plasma lipoproteins and heparin-releasable lipases. In: Bardin CW, Milgrom E, Mauvais-Jarvis P, eds. Progesterone and progestins. New York: Raven Press, 1983:411–20.
Cited by
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Mosca, L., Manson, J. E., Sutherland, S. E., Langer, R. D., Manolio, T., & Barrett-Connor, E. (1997) · Circulation · doi:10.1161/01.cir.96.7.2468 · Cited by 736
World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contarception (1995) · The Lancet · doi:10.1016/s0140-6736(95)91926-0 · Cited by 631
Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline
Blumer, I., Hadar, E., Hadden, D. R., Jovanovič, L., Mestman, J. H., Murad, M. H., & Yogev, Y. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2465 · Cited by 561
“Progestinonly oral contraceptives do not affect blood glucose values or BP in women with type 1 diabetes (231, 232); however, there is some limited evidence that these medications increase the risk for later developing type 2 diabetes in women who have had gestational diabetes (222, 233).”
Oral Contraceptives and the Risk of Myocardial Infarction
Tanis, B. C., van den Bosch, M. A. A. J., Kemmeren, J. M., Cats, V. M., Helmerhorst, F. M., Algra, A., van der Graaf, Y., & Rosendaal, F. R. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003216 · Cited by 367
Metadata
- Authors
- Godsland, I. F., Crook, D., Simpson, R., Proudler, T., Felton, C., Lees, B., Anyaoku, V., Devenport, M., & Wynn, V.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1990-11-15
- Volume
- 323
- Issue
- 20
- Pages
- 1375-1381
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2596242802
- Cited by
- 417
- References
- 38
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 9 · 2023: 12 · 2022: 5 · 2021: 10 · 2020: 3 · 2019: 7 · 2018: 7 · 2017: 13 · 2016: 11 · 2015: 8 · 2014: 9 · 2013: 11 · 2012: 13
- FWCI
- 25.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01hd052907-001)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (N01-HD-52907)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- oral contraceptives, levonorgestrel, norethisterone, desogestrel, ethinyl estradiol, lipid metabolism, carbohydrate metabolism, triglycerides, LDL cholesterol, HDL cholesterol, HDL subfractions, apolipoproteins, insulin, glucose tolerance, coronary heart disease risk, women's health, progestin-only contraception
- MeSH terms
- Adolescent, Adult, Blood Glucose, C-Peptide, Cholesterol, Contraceptives, Oral, Combined, Contraceptives, Oral, Sequential, Ethynodiol Diacetate, Female, Humans, Insulin, Cholesterol, HDL, Cholesterol, LDL, Middle Aged, Norethindrone, Norgestrel, Norpregnenes, Triglycerides, Levonorgestrel, Desogestrel, Progesterone Congeners, Carbohydrate Metabolism, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effects of Different Formulations of Oral Contraceptive Agents on Lipid and Carbohydrate Metabolism. https://app.cochat.ai/papers/10.1056/nejm199011153232003
- The paper
- Godsland, I. F., Crook, D., Simpson, R., Proudler, T., Felton, C., Lees, B., Anyaoku, V., Devenport, M., & Wynn, V. (1990). The Effects of Different Formulations of Oral Contraceptive Agents on Lipid and Carbohydrate Metabolism. New England Journal of Medicine. https://doi.org/10.1056/nejm199011153232003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.